We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer’s Injectable Revatio Approved for PAH Indication
Pfizer’s Injectable Revatio Approved for PAH Indication
November 25, 2009
The FDA has approved Pfizer’s injectable formulation of the pulmonary arterial hypertension (PAH) drug Revatio.